Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.18 CAD | -5.26% | -2.70% | -14.29% |
Feb. 14 | Helix BioPharma Corp. Appoints Praveen Varshney as Corporate Secretary | CI |
Feb. 14 | Helix BioPharma Corp. Appoints Praveen Varshney as Chief Financial Officer | CI |
Sales 2022 | - | Sales 2023 | - | Capitalization | 42M 56.97M |
---|---|---|---|---|---|
Net income 2022 | -6M -8.14M | Net income 2023 | -6M -8.14M | EV / Sales 2022 | - |
Net cash position 2022 | 784K 1.06M | Net cash position 2023 | 808K 1.1M | EV / Sales 2023 | - |
P/E ratio 2022 |
-4.33
x | P/E ratio 2023 |
-6.45
x | Employees | 9 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 78.35% |
1 day | -5.26% | ||
1 week | -2.70% | ||
Current month | -2.70% | ||
1 month | +5.88% | ||
3 months | -14.29% | ||
6 months | -28.00% | ||
Current year | -14.29% |
Managers | Title | Age | Since |
---|---|---|---|
Jacek Antas
CEO | Chief Executive Officer | - | 22-04-17 |
Director of Finance/CFO | 59 | Feb. 13 | |
Chief Tech/Sci/R&D Officer | - | 22-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | - | 22-04-17 | |
Jacek Antas
CEO | Chief Executive Officer | - | 22-04-17 |
Malgorzata Laube
BRD | Director/Board Member | - | 22-12-07 |
Date | Price | Change | Volume |
---|---|---|---|
24-03-18 | 0.18 | -5.26% | 1,000 |
24-03-15 | 0.19 | +2.70% | 500 |
24-03-13 | 0.185 | -2.63% | 3,000 |
24-03-12 | 0.19 | +2.70% | 21,120 |
Delayed Quote Toronto S.E., March 18, 2024 at 09:30 am EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-14.29% | 28.79M | |
+9.72% | 46.21B | |
+35.14% | 40.04B | |
+4.84% | 39.92B | |
-9.43% | 28.33B | |
+17.47% | 27.43B | |
-22.99% | 18.57B | |
+10.88% | 13.46B | |
+27.53% | 12.02B | |
-6.84% | 11.3B |